+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Global Myasthenia Gravis Diagnosis and Treatment Market Forecast, 2018-2023

  • ID: 4751439
  • Report
  • January 2019
  • Region: Global
  • Orion Market Research Private Limited
1 of 3

Enquire about COVID-19 updates for this product.

Enquire Now

FEATURED COMPANIES

  • Abbott Laboratories, Inc.
  • Beckman Coulter, Inc.
  • bioMérieux S.A.
  • ELITech Group
  • Grifols, S.A.
  • Merck KGaA
  • MORE
Myasthenia gravis is a chronic autoimmune disorder in which the person loses control over voluntary muscles. A person with such disease might not be able to breathe properly, lift objects and do activities that require voluntary muscle. The condition arises due to the error in transmission of impulses to muscles, the human body produces antibodies due to immune disorder which affects the healthy tissue. The neuromuscular junction is damaged thereby reducing the effect of neurotransmitter acetylcholine which facilitates the communication between nerve cells and muscles. The rise in geriatric population contributes significantly to the growth of this market as the person above 60 is more prone to such diseases. The government approval for use of monoclonal antibodies for treatment is yet another contributing factor in the growth of the market. The stressful lifestyle of individual and exposure to heat may also lead to myasthenia gravis. The major factor restraining the growth of the market is the high cost of drugs and the significant side effects of immunosuppressant drugs. The research and development in novel drug development will drive the future market for myasthenia gravis drugs.

The market is divided into North America, Europe, Asia-Pacific and Rest of the World. North America has the largest market for myasthenia gravis attributed to the presence of a large number of patients in the region. According to myasthenia gravis foundation of America, 20 people out of 100000 suffers from the disease in the US. The region also has the most advanced healthcare infrastructure which is driving the technological advancement in the market. The UK in the European region holds the second place in prevalence ranking after the US, the region also has the well-developed infrastructure for healthcare. The Asia-Pacific region will grow significantly due to the increase in expenditure for procurement of better healthcare infrastructure in near future.

The competition in myasthenia gravis market is tough due to the presence of a large number of market player. The market players are engaged in providing various type of drugs and plasma therapies for the treatment of diseases. Additionally, R&D in the field of novel drugs such as monoclonal antibodies is also the boon for the entire mankind. The key players in the global myasthenia gravis market are Alexion Pharmaceuticals, Inc., Argenx SE, Avadel Pharmaceutical PLC, Catalyst Pharmaceuticals, Inc., CSL Behring, Curavac, Inc, and Cytokinetics, Inc. The companies are engaged in rapid research and development for the development of effective treatment measure for the disease.

Research Methodology

The market study of global myasthenia gravis market is incorporated by extensive primary and secondary research. Secondary research has been conducted to refine the available data to break down the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior and macroeconomic factors. Numbers extracted from Secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings the authenticity of our reports.

Secondary Sources Include
  • Financial reports of companies involved in the market
  • Authentic Public Databases such as Myasthenia Gravis Foundation (MGF) and Muscular Dystrophy Association (MDA).
  • Whitepapers such as research papers and news blogs
  • Company websites and their product catalog.
The report is intended for pharmaceutical companies and researchers in the market, investing companies, government organizations for overall market analysis and competitive analysis. The report will serve as a source for 360-degree analysis of the market thoroughly integrating different models delivering insights into the market for better business decisions.

Market Segmentation

Global myasthenia gravis market is segmented on the basis of various regions and below mentioned segments:
1. Global Myasthenia Gravis Market Research and Analysis by Diagnosis
2. Global Myasthenia Gravis Market Research and Analysis by Treatment
3. Global Myasthenia Gravis Market Research and Analysis by End-User

The Report Covers
  • Comprehensive research methodology of the global myasthenia gravis market.
  • This report also includes a detailed and extensive market overview with key analyst insights.
  • An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
  • Analysis of regional regulations and other government policies impacting the global myasthenia gravis market.
  • Insights about market determinants which are stimulating the global myasthenia gravis market.
  • Detailed and extensive market segments with regional distribution of forecast revenues.
  • Extensive profiles and recent developments of market players.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Abbott Laboratories, Inc.
  • Beckman Coulter, Inc.
  • bioMérieux S.A.
  • ELITech Group
  • Grifols, S.A.
  • Merck KGaA
  • MORE
1. Report Summary
1.1. Research Methods and Tools
1.2. Market Breakdown
1.2.1. By Segments
1.2.2. By Geography
1.2.3. By Stakeholders

2. Market Overview and Insights
2.1. Definition
2.2. Analyst Insights & Current Market Trends
2.2.1. Key Findings
2.2.2. Recommendations
2.2.3. Conclusion
2.3. Regulation

3. Market Determinants
3.1. Motivators
3.1.1. Rising Prevalence of Infectious Diseases
3.1.2. Extensive Application in Oncology
3.1.3. Growing Number of FDA-Cleared and Approved Tests
3.1.4. Growing Demand for Accurate and Cost-Effective Diagnostic Solutions
3.2. Restraints
3.2.1. Regulatory Issues and Hurdles
3.2.2. Lack of Medical Infrastructure in Developing and Under Developed Countries
3.3. Opportunities
3.3.1. Growing Demand for Personalized Treatment
3.3.2. Technological Advancement in Sequencing and Point of Care Testing Devices

4. Market Segmentation
4.1. Global Molecular Diagnostics Market by Technology
4.1.1. Polymerase Chain Reaction (PCR)
4.1.2. In Situ Hybridization (ISH)
4.1.3. Mass Spectrometry (MS)
4.1.4. DNA Microarray
4.1.5. Next-Generation Sequencing (NGS)
4.1.6. Transcription Mediated Amplification
4.1.7. Isothermal Nucleic Acid Amplification
4.2. Global Molecular Diagnostics Market by Product
4.2.1. Testing instruments
4.2.2. Diagnostic Reagents and Kits
4.3. Global Molecular Diagnostics Market by Application
4.3.1. Infectious Diseases
4.3.2. Cancer
4.3.3. Cardiovascular Disease
4.3.4. Genetic Testing
4.3.5. Forensic Science
4.3.6. Neurological Disease
4.3.7. Other (Microbiology)
4.4. Global Molecular Diagnostics Market by End-User
4.4.1. Hospitals
4.4.2. Diagnostic Centres
4.4.3. Research Institute

5. Competitive Landscape
5.1. Key Strategies
5.2. Key Company Analysis

6. Regional Analysis
6.1. North America
6.1.1. United States
6.1.2. Canada
6.2. Europe
6.2.1. UK
6.2.2. Germany
6.2.3. Spain
6.2.4. France
6.2.5. Italy
6.2.6. Rest of Europe
6.3. Asia-Pacific
6.3.1. China
6.3.2. Japan
6.3.3. India
6.3.4. Rest of Asia-Pacific
6.4. Rest of the World

7. Company Profiles
7.1. Abbott Laboratories, Inc.
7.2. Agilent Technologies, Inc.
7.3. AltheaDX, Inc.
7.4. AutoGenomics, Inc.
7.5. Beckman Coulter, Inc.
7.6. Becton Dickinson and Co.
7.7. Biocartis N.V.
7.8. bioMérieux S.A.
7.9. Bio-Rad Laboratories, Inc.
7.10. CareDX, Inc.
7.11. Danaher Corp.
7.12. ELITech Group
7.13. F. Hoffmann-La Roche, Ltd.
7.14. Genetic Technologies, Ltd.
7.15. GenMark Diagnostics, Inc.
7.16. Genomic Health, Inc.
7.17. Grifols, S.A.
7.18. Hologic, Inc.
7.19. HTG Molecular Diagnostics, Inc.
7.20. MDxHealth Group
7.21. Merck KGaA
7.22. Oxford Nanopore Technologies Ltd.
7.23. QIAGEN N.V.
7.24. Sequenom Laboratories
7.25. Siemens AG
7.26. Source BioScience UK Limited
7.27. Thermo Fisher Scientific, Inc.
7.28. Veracyte, Inc.
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Abbott Laboratories, Inc.
  • Agilent Technologies, Inc.
  • AltheaDX, Inc.
  • AutoGenomics, Inc.
  • Beckman Coulter, Inc.
  • Becton Dickinson and Co.
  • Biocartis N.V.
  • bioMérieux S.A.
  • Bio-Rad Laboratories, Inc.
  • CareDX, Inc.
  • Danaher Corp.
  • ELITech Group
  • F. Hoffmann-La Roche, Ltd.
  • Genetic Technologies, Ltd.
  • GenMark Diagnostics, Inc.
  • Genomic Health, Inc.
  • Grifols, S.A.
  • Hologic, Inc.
  • HTG Molecular Diagnostics, Inc.
  • MDxHealth Group
  • Merck KGaA
  • Oxford Nanopore Technologies Ltd.
  • QIAGEN N.V.
  • Sequenom Laboratories
  • Siemens AG
  • Source BioScience UK Limited
  • Thermo Fisher Scientific, Inc.
  • Veracyte, Inc.
Note: Product cover images may vary from those shown
Adroll
adroll